Anzeige
Mehr »
Login
Donnerstag, 30.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Die neuen Aktien-Stars der nächsten Rallye-Stufe im Uransektor
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EEZB | ISIN: US72941H5090 | Ticker-Symbol: XMP0
Berlin
30.05.24
08:08 Uhr
1,918 Euro
-0,028
-1,44 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PLUS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PLUS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,8541,96618:42
1,8541,96618:39

Aktuelle News zur PLUS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.05.PLUS THERAPEUTICS, INC. - 8-K, Current Report2
17.05.Plus Therapeutics Inc.: Plus Therapeutics Announces New Employment Inducement Grants123AUSTIN, Texas, May 17, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
► Artikel lesen
16.05.Earnings call: Plus Therapeutics reveals Q1 2024 financials, clinical progress3
15.05.Plus Therapeutics Inc reports results for the quarter ended in March - Earnings Summary4
15.05.Plus Therapeutics Inc. Q1 Loss Decreases, Beats Estimates325WASHINGTON (dpa-AFX) - Plus Therapeutics Inc. (PSTV) reported Loss for first quarter that decreased from last year and beat the Street estimates.The company's earnings totaled -$3.26 million...
► Artikel lesen
15.05.Plus Therapeutics Inc.: Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights49Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus' clinical brain cancer program...
► Artikel lesen
15.05.PLUS THERAPEUTICS, INC. - 10-Q, Quarterly Report2
14.05.Plus Therapeutics Q1 2024 Earnings Preview3
13.05.Plus Therapeutics Inc.: Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 20243
09.05.PLUS THERAPEUTICS, INC. - 8-K, Current Report2
09.05.Plus Therapeutics Inc.: Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial127Company acquired assets for the synergistic leptomeningeal metastases (LM) diagnostic platform, "CNSide" and discussed potential partnering opportunities CNSide can significantly improve LM diagnostic...
► Artikel lesen
08.05.Plus Therapeutics Inc.: Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial3
06.05.Plus Therapeutics Inc.: Plus Therapeutics Announces Private Placement Financing of up to $18 Million11
22.04.Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense5
09.04.Plus Therapeutics Inc.: Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team162The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus' scientific...
► Artikel lesen
14.03.Plus Therapeutics faces Nasdaq delisting over equity shortfall9
13.03.PLUS THERAPEUTICS, INC. - 8-K, Current Report3
08.03.PLUS THERAPEUTICS, INC. - S-1/A, General form for registration of securities4
07.03.Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Call Transcript5
06.03.Earnings call: Plus Therapeutics shows progress in CNS cancer trials3
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1